Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q2 2025 Earnings Report

Xenetic Biosciences logo
$2.97 +0.06 (+2.06%)
Closing price 08/7/2025 03:59 PM Eastern
Extended Trading
$2.96 -0.01 (-0.47%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.64
Beat/Miss
N/A
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.48 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat